Phase 2 N=6 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Breast Cancer
Primary: Progression-Free Survival — 5.8 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=208 A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis (MS)
Primary: Mean Overall Response Score (ORS) at Week 52 — 0.04; -0.17; -0.17 score on a scale
Phase 4 N=84 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
Surgery · Coronary Artery Disease
Primary: Time to Extubation — 10.4; 6 Minutes
Phase 4 N=2,634 Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
Sepsis · AKI · Neurotoxicity
Primary: Acute Kidney Injury (AKI) Ordinal Scale — 910; 952; 86; 100 Participants
Phase 3 N=1,069 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Biliary Tract Carcinoma
Primary: Overall Survival (OS) — 12.7; 10.9 Months — p=0.0034
N/A N=129 Efficacy Trial of the FMF Connect Mobile Health Intervention
Fetal Alcohol Spectrum Disorders
Primary: Eyberg Child Behavior Inventory - Intensity at Baseline and 12-week Follow-Up — 68.33; 69.13; 68.40; 64.47 T-score — p=.602
N/A N=22 Immersive Virtual Reality Bicycling for Persons With Parkinson's Disease
Parkinson Disease
Primary: Neuromuscular Intensity (Bicycling Cadence, Revolutions Per Minute) - Feedback — 85.44 revolutions per minute (rpm) — p=<0.001
Phase 3 N=59 Study of Remdesivir in Participants Below 18 Years Old With COVID-19
COVID-19
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 91.7; 58.3; 75.0; 58.3 percentage of participants
N/A N=3 Caregiver Support in the Context of Multiple Chronic Conditions
Caregiver Burnout
Primary: Quality of Life as Assessed by the Short Form Health Survey — 72.3; 74.1; 70.4; 76.1 units on a scale
Phase 2 N=326 A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 82.1; 81.2; 81.6; 82.9 score on a scale — p=0.6003
Phase 3 N=133 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Moderate to Severe Atopic Hand and Foot Dermatitis
Primary: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 — 16.7; 40.3 Percentage of participants — p==0.0030
Phase 2 N=96 Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR
Dyslipidemia
Primary: Estimated Percentage Change in Fasting Triglyceride(s) (TG) — -41.57; -36.79; -38.94 Percent Change — p=0.3084
N/A N=20 Providing Accessible Diagnostic Evaluations and Psychoeducation for Autism Spectrum Disorder in Rural Southwest Virginia
Autism Spectrum Disorder
Primary: Number of Parent-child Pairs Who Completed Study Sessions Assessed by Parental Attendance — 11; 9; 11; 9 parent-child pairs
N/A N=234 Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
Substance Use · HIV Infections · HCV Infection
Primary: Change in Substance Use Frequency — -11.2; -5.5 Days of drug use
Phase 2 N=5 Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in the Chronic Respiratory - Self Administered Individualized (CRQ-SAI) Dyspnea Domain Score at 12 Weeks — 2.00; -0.20 Score on a scale